CD19 and lymphoma: CAR T-cell therapy targeting CD19 (CART19) may also play a role in lymphoma reprograming including transdifferentiation by enabling outgrowth of the preexisting non-lymphoid subclone, due to the CART19-mediated eradication of the dominant lymphoma clone expressing CD19 (29).